Cite
HARVARD Citation
Salous, T. et al. (2023). A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029. Cancer. 129 (2), pp. 264-271. [Online].